ATE554109T1 - Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür - Google Patents
Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafürInfo
- Publication number
- ATE554109T1 ATE554109T1 AT04797921T AT04797921T ATE554109T1 AT E554109 T1 ATE554109 T1 AT E554109T1 AT 04797921 T AT04797921 T AT 04797921T AT 04797921 T AT04797921 T AT 04797921T AT E554109 T1 ATE554109 T1 AT E554109T1
- Authority
- AT
- Austria
- Prior art keywords
- applications
- specific antibody
- antibody sam
- sam
- adenocarcinoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03026161A EP1531162A1 (de) | 2003-11-14 | 2003-11-14 | Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen |
PCT/EP2004/012970 WO2005047332A1 (en) | 2003-11-14 | 2004-11-12 | Adenocarcinoma specific antibody sam-6, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE554109T1 true ATE554109T1 (de) | 2012-05-15 |
Family
ID=34429369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04797921T ATE554109T1 (de) | 2003-11-14 | 2004-11-12 | Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür |
Country Status (7)
Country | Link |
---|---|
US (2) | US8163552B2 (de) |
EP (3) | EP1531162A1 (de) |
JP (1) | JP2008507951A (de) |
AT (1) | ATE554109T1 (de) |
AU (1) | AU2004289821B2 (de) |
CA (1) | CA2545454C (de) |
WO (1) | WO2005047332A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2322559A3 (de) | 2002-07-04 | 2011-08-03 | Patrys Limited | Neoplasma-spezifische Antikörper und deren Verwendungen |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
EP1531162A1 (de) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
JP2010510772A (ja) * | 2006-11-27 | 2010-04-08 | パトリス リミテッド | 新生細胞における新規なグリコシル化ペプチド標的 |
WO2009104100A2 (en) * | 2008-02-19 | 2009-08-27 | Patrys Limited | Antibody combinations, and methods of making and using same |
AU2010210312A1 (en) * | 2009-02-09 | 2011-08-04 | Patrys Limited | SAM-6 variants, target and methods of use |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
DE3722647A1 (de) | 1987-07-09 | 1989-01-19 | Gerhard Ohlenschlaeger | Galenische verwendung eines tripeptids als arzneimittel |
DE4107154A1 (de) | 1990-10-11 | 1992-04-16 | Boehringer Mannheim Gmbh | Monoklonale antikoerper gegen melanom |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
GB9105292D0 (en) | 1991-03-13 | 1991-04-24 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
US5639863A (en) * | 1994-06-21 | 1997-06-17 | Dan; Michael D. | Human monoclonal antibodies specific to cell cycle independent glioma surface antigen |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
WO1997002479A2 (en) | 1995-06-30 | 1997-01-23 | Yale University | Human monoclonal anti-tumor antibodies |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
AU4982097A (en) | 1996-10-18 | 1998-05-15 | Board Of Regents, The University Of Texas System | Anti-erbb2 antibodies |
CA2287911C (en) * | 1997-05-15 | 2014-05-06 | Genentech, Inc. | Apo-2 receptor |
US6185924B1 (en) | 1997-10-17 | 2001-02-13 | Hitachi, Ltd. | Gas turbine with turbine blade cooling |
EP0927757A1 (de) | 1997-12-03 | 1999-07-07 | Leadd B.V. | Verfahren und Mitteln um Apoptose zu induzieren durch Interferenz mit Bip-ähnliche Proteine |
JP2002511259A (ja) * | 1998-04-09 | 2002-04-16 | ジェンセット | 5’estおよびコードされるヒトタンパク質 |
US6846637B1 (en) | 1998-06-18 | 2005-01-25 | Imed Ab | Fas peptides and antibodies for modulating apoptosis |
JP4638035B2 (ja) * | 1998-08-28 | 2011-02-23 | ジェネンテック, インコーポレイテッド | ヒト抗−IX/IXa因子抗体 |
GB9822115D0 (en) | 1998-10-09 | 1998-12-02 | King S College London | Treatment of inflammatory disease |
ES2219108T3 (es) | 1998-12-22 | 2004-11-16 | Heinz Peter Vollmers | Sustancia para producir medicamentos antitumorales altamente eficaces y su metodo correspondiente. |
TR200102715T2 (tr) | 1999-03-25 | 2002-09-23 | Knoll Gmbh | Beşeri IL-12'yi bağlayan beşeri antikorlar ve bunları üretmek için yöntemler. |
US7049132B1 (en) | 1999-06-28 | 2006-05-23 | University Of Southern California | Stress-responsive induction of a therapeutic agent and methods of use |
MXPA02001911A (es) * | 1999-08-24 | 2003-07-21 | Medarex Inc | Anticuerpos ctla-4 humanos y sus usos. |
US6677442B1 (en) | 1999-10-29 | 2004-01-13 | University Of Kentucky Research Foundation | Nucleic acid encoding human REV1 protein |
MXPA02008144A (es) | 2000-02-23 | 2002-11-29 | Amgen Inc | Agentes de enlace selectivos antagonistas de la proteina de enlace de osteoprotegerina. |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7220840B2 (en) * | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
AU6842701A (en) | 2000-06-16 | 2002-01-14 | Human Genome Sciences Inc | Antibodies that immunospecifically bind to blys |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
CA2426710A1 (en) * | 2000-11-08 | 2002-10-10 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
EP1390741B1 (de) * | 2001-04-17 | 2012-10-31 | Abmaxis, Inc. | Auf strukturen beruhende konstruktion einer bibliothek menschlicher antikörper |
IL160029A0 (en) | 2001-07-24 | 2004-06-20 | Receptor, the use thereof, and mouse antibodies | |
US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
US20040048243A1 (en) | 2001-09-07 | 2004-03-11 | Wadih Arap | Methods and compositions for in vitro targeting |
EP1461428B1 (de) | 2001-12-03 | 2012-03-21 | Alexion Pharmaceuticals, Inc. | Verfahren zur Herstellung von Hybridantikörper |
DE10210427A1 (de) * | 2002-03-09 | 2003-10-09 | Hans Konrad Mueller-Hermelink | Humaner monoklonaler Antikörper |
WO2003084477A2 (en) | 2002-03-29 | 2003-10-16 | Centocor, Inc. | Mammalian cdr mimetibodies, compositions, methods and uses |
ATE328906T1 (de) * | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
EP2322559A3 (de) | 2002-07-04 | 2011-08-03 | Patrys Limited | Neoplasma-spezifische Antikörper und deren Verwendungen |
DE10230516A1 (de) | 2002-07-06 | 2004-01-15 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
AU2002364501A1 (en) | 2002-08-30 | 2004-03-19 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
SE0302312D0 (sv) | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
DE10311248A1 (de) | 2003-03-14 | 2004-09-30 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper |
WO2005001052A2 (en) | 2003-06-06 | 2005-01-06 | University Of Massachusetts | Modulation of apoptosis |
WO2005045428A2 (en) | 2003-10-27 | 2005-05-19 | University Of Southern California | Methods and compositions for modulating apoptosis |
NZ577824A (en) | 2003-11-12 | 2010-10-29 | Patrys Ltd | Methods of identifying neoplasm-specific antibodies and uses thereof |
DE10353175A1 (de) | 2003-11-14 | 2005-06-16 | Müller-Hermelink, Hans Konrad, Prof. Dr. | Humaner monoklonaler Antikörper mit fettsenkender Wirkung |
EP1531162A1 (de) | 2003-11-14 | 2005-05-18 | Heinz Vollmers | Antikörper SAM-6, der spezifisch von Adenocarzinom ist, und dessen Verwendungen |
WO2005065418A2 (en) | 2003-12-31 | 2005-07-21 | Board Of Regents, The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy |
GB0404936D0 (en) | 2004-03-04 | 2004-04-07 | Univ London | Screen |
DE102004015179A1 (de) | 2004-03-25 | 2005-10-13 | Oncomab Gmbh | Antigen des PM-2 Antikörpers und dessen Verwendung |
JP2010510772A (ja) | 2006-11-27 | 2010-04-08 | パトリス リミテッド | 新生細胞における新規なグリコシル化ペプチド標的 |
AU2010210312A1 (en) | 2009-02-09 | 2011-08-04 | Patrys Limited | SAM-6 variants, target and methods of use |
-
2003
- 2003-11-14 EP EP03026161A patent/EP1531162A1/de not_active Withdrawn
-
2004
- 2004-11-12 US US10/579,290 patent/US8163552B2/en not_active Expired - Fee Related
- 2004-11-12 WO PCT/EP2004/012970 patent/WO2005047332A1/en active Application Filing
- 2004-11-12 EP EP04797921A patent/EP1709083B1/de not_active Not-in-force
- 2004-11-12 AT AT04797921T patent/ATE554109T1/de active
- 2004-11-12 JP JP2006543403A patent/JP2008507951A/ja active Pending
- 2004-11-12 CA CA2545454A patent/CA2545454C/en not_active Expired - Fee Related
- 2004-11-12 AU AU2004289821A patent/AU2004289821B2/en not_active Ceased
- 2004-11-12 EP EP10182086A patent/EP2341077A1/de not_active Withdrawn
-
2012
- 2012-03-23 US US13/428,832 patent/US8741296B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP2341077A1 (de) | 2011-07-06 |
AU2004289821A1 (en) | 2005-05-26 |
WO2005047332A1 (en) | 2005-05-26 |
EP1709083B1 (de) | 2012-04-18 |
EP1709083A1 (de) | 2006-10-11 |
US8163552B2 (en) | 2012-04-24 |
US20130039849A1 (en) | 2013-02-14 |
CA2545454C (en) | 2016-09-13 |
CA2545454A1 (en) | 2005-05-26 |
AU2004289821B2 (en) | 2011-10-06 |
US8741296B2 (en) | 2014-06-03 |
JP2008507951A (ja) | 2008-03-21 |
US20080108133A1 (en) | 2008-05-08 |
EP1531162A1 (de) | 2005-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL301089I2 (nl) | imlifidase | |
NO20063624L (no) | FC region varianter | |
CY1117124T1 (el) | ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ | |
CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
ATE541857T1 (de) | Optimierte fc-varianten und herstellungsverfahren dafür | |
CY1113224T1 (el) | Νεο αντισωμα αντι-ρlgf | |
HUP0402029A2 (hu) | Peptidalapú multimer célzott kontrasztanyagok | |
CY1114690T1 (el) | Αντισωματα αντι-nrr notch1 και μεθοδοι χρησεις αυτων | |
CY1112862T1 (el) | Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα | |
CY1112507T1 (el) | Μορια αντισωματος που εχουν ειδικοτητα για την ανθρωπινη ιl-1β | |
BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
NO20091976L (no) | Nye forbindelser | |
ATE525392T1 (de) | Regulatorische t-zellen-epitopen sowie zusammensetzungen damit und anwendungen davon | |
CY1110759T1 (el) | Παραλλαγες ανοσοσφαιρινων και χρησεις αυτων | |
DK1771732T3 (da) | Taxol-immunassay | |
DE60321041D1 (de) | Antikörper gegen krebsantigen tmeff2 und seine anwendungen | |
ATE411300T1 (de) | Neue cysteine protease hemmers und ihre therapeutische anwendungen | |
DK1875237T3 (da) | Docetaxel-immunassay | |
EA200602281A1 (ru) | Гетероарилсульфоны и сульфонамиды и их терапевтические применения | |
DE60312895D1 (de) | Emulsionen mit oberflächenmodifizierten organischen molekülen | |
DE602004009824D1 (de) | Analyse von massenspektraldaten in den ruhigen gebieten | |
ATE554109T1 (de) | Adenocarcinomspezifischer antikörper sam-6 und anwendungen dafür | |
SE0301650D0 (sv) | Novel compounds | |
NO20053903D0 (no) | Nukleotidlipidesterderivater. | |
ATE494307T1 (de) | Neoplasma-spezifische antikörper und deren verwendungen |